FOXP1调控急性髓系白血病细胞的氧化应激、SIRT1表达及化疗耐药
研究探讨FOXP1在人造血干祖细胞与急性髓系白血病细胞氧化应激防御中的作用。FOXP1表达与细胞遗传学正常AML患者较差生存相关;敲低FOXP1升高CD34+CD38+细胞超氧阴离子并增敏化疗,该抗氧化作用不依赖FOXO而通过稳定SIRT1蛋白实现。
要点
- FOXP1表达水平与细胞遗传学正常AML患者较差生存结局相关。
- 敲低FOXP1升高人定向CD34+CD38+细胞超氧阴离子,但不改变富干细胞CD34+CD38-或AML细胞。
- FOXP1通过稳定SIRT1蛋白上调其表达,不依赖FOXO及SOD1/2、过氧化氢酶变化。
核心结论
- FOXP1是髓系祖细胞氧化应激的新保护因子,不依赖FOXO而通过SIRT1发挥作用,并促进AML化疗耐药。
- 作者提出FOXP1表达/活性是克服AML造血干祖细胞耐药的潜在靶点。
研究设计与样本
- 在人造血干祖细胞与急性髓系白血病细胞中开展体外实验,结合患者生存关联分析。
主要发现
- FOXP1表达水平与细胞遗传学正常AML患者较差生存结局相关。
- 敲低FOXP1升高人定向CD34+CD38+细胞的超氧阴离子水平,但不改变富干细胞CD34+CD38-造血干祖细胞或AML细胞的超氧阴离子水平。
- 敲低FOXP1增强NRF2活性并增加细胞氧化应激。
- FOXP1对FOXO1/3/4表达无影响;遗传或药理抑制FOXO未改变人造血干祖细胞或AML细胞的超氧阴离子水平。
- FOXP1抗氧化活性不依赖超氧化物歧化酶1和2或过氧化氢酶表达变化,而是通过稳定SIRT1蛋白上调SIRT1表达。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transcription factor Forkhead box P1 (FOXP1) belongs to the same protein family as the FOXOs that are well-known regulators of murine hematopoietic stem progenitor cell (HSPC) maintenance via dampening oxidative stress. FOXP1 and FOXOs can play opposite, or similar, roles depending on cell context; they can crossregulate each other's expression. In a previous study, we have shown that FOXP1 contributes to healthy human HSPC and acute myeloid leukemia (AML) cell growth. Here, we investigated the role of FOXP1 in HSPCs and AML cell oxidative stress defense in a human context. FOXP1 expression level was associated with an inferior survival outcome in patients with cytogenetically normal AML. FOXP1 knockdown enhanced superoxide anion levels of human-committed CD34+CD38+ cells but not stem cell-enriched CD34+CD38- HSPCs or AML cells in vitro. FOXP1 knockdown triggered enhanced NRF2 activity and increased cell oxidative stress. FOXP1 had no impact on FOXO1/3/4 expression in these cells; genetic and pharmacological inhibition of FOXOs did not change superoxide anion levels of human HSPCs or AML cells. Moreover, FOXP1 antioxidant activity was independent of changes in expression of superoxide dismutase 1 and 2 or catalase. Instead, FOXP1 upregulated expression of the stress sensor SIRT1 by stabilizing SIRT1 protein. FOXP1 loss sensitized AML cells to chemotherapy. Together, this study identified FOXP1 as a new safeguard against myeloid progenitor oxidative stress, which works independently of FOXOs but through SIRT1 and contributes to AML chemoresistance. It proposes FOXP1 expression/activity as a promising target to overcome drug resistance of AML HSPCs.
引用
- Levavasseur F, Oussous S, Zubaidan T, et al. FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells. Blood Adv. 2023. PMID: 36930820. doi:10.1182/bloodadvances.2022008585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。